List of Excipients in Branded Drug SEREVENT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	SEREVENT	salmeterol xinafoate	0173-0521	LACTOSE
Dispensing Solutions Inc	SEREVENT	salmeterol xinafoate	68258-8961	LACTOSE

Serevent Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: November 3, 2026

Serevent is a salmeterol xinafoate dry-powder inhaler marketed as Serevent Diskus. Its US formulation uses lactose monohydrate as the principal carrier excipient, with milk-protein content disclosed as a clinical consideration. The commercial opportunity is therefore less likely to come from a new active-ingredient patent and more likely to involve carrier engineering, dose uniformity, inhaler-device performance, moisture control, and differentiated combination products.

Serevent is a long-acting beta2-adrenergic agonist, or LABA. It is approved for twice-daily maintenance treatment of asthma and chronic obstructive pulmonary disease, but it is not approved for relief of acute bronchospasm. For asthma, the FDA requires LABA use with an inhaled corticosteroid rather than LABA monotherapy. [1]

What excipients are used in Serevent Diskus?

Serevent Diskus contains salmeterol xinafoate blended with lactose monohydrate. The lactose functions primarily as a carrier in the dry-powder formulation.

Product attribute	Serevent Diskus
Active ingredient	Salmeterol xinafoate
Delivered salmeterol dose	50 mcg per blister
Dosage form	Dry powder for oral inhalation
Device	Diskus multidose inhaler
Principal excipient	Lactose monohydrate
Propellant	None
Preservative	None disclosed for the powder formulation
Key formulation issue	Low-dose uniformity and powder dispersion
Clinical excipient issue	Lactose may contain trace milk proteins

The label states that each blister contains salmeterol xinafoate equivalent to 50 mcg of salmeterol and a mixture of lactose monohydrate, which may contain milk proteins. Patients with severe milk-protein allergy are warned against using the product. [1]

The formulation contains a very small drug load relative to the lactose carrier. That ratio creates the central technical challenge: the formulation must deliver consistent salmeterol doses across the life of the inhaler despite variation in powder flow, humidity, carrier adhesion, deagglomeration, inhalation effort, and device orientation.

How does the Serevent excipient system work?

Lactose monohydrate is used as a carrier to improve handling and dose metering of the micronized drug. Salmeterol xinafoate particles are too small and cohesive to be filled and dispersed reliably without a larger carrier or another engineered particle system.

A conventional lactose-carrier DPI depends on several interactions:

1. Micronized drug particles adhere to lactose carrier particles during blending.
2. The patient’s inhalation force separates drug from the carrier.
3. The device disperses the powder into an aerosol.
4. The respirable fraction reaches the lower airways.
5. Larger lactose particles remain primarily in the oropharyngeal region and are swallowed.

The commercial performance of the formulation depends on carrier particle-size distribution, surface roughness, fines content, water activity, blending energy, and drug crystallinity. A formulation that has acceptable blend uniformity may still fail aerodynamic performance testing if the drug remains too strongly attached to the carrier or forms agglomerates during storage.

What excipient attributes matter most?

Excipient attribute	Commercial relevance
Lactose particle-size distribution	Controls flow, metering, and dispersion
Surface morphology	Affects drug adhesion and detachment
Fine-lactose fraction	Can improve aerosolization but may increase variability
Moisture content	Affects cohesion, stability, and emitted dose
Protein contamination control	Relevant to milk-allergy labeling and risk management
Batch consistency	Supports device and dose uniformity specifications
Microbial quality	Required for inhalation-grade material
Supply continuity	Reduces manufacturing and regulatory change risk

What commercial opportunities exist for Serevent excipients?

The strongest opportunities are in high-performance inhalation excipients and formulation services rather than commodity lactose alone.

Engineered lactose carriers

A supplier could offer lactose grades optimized for salmeterol-like low-dose LABA formulations. Differentiation may include controlled fines, narrow particle-size distribution, tailored surface roughness, and low moisture variability.

The commercial value is highest when the excipient is linked to measurable performance improvements, such as:

• higher fine-particle dose;
• lower delivered-dose variability;
• improved content uniformity;
• reduced dependence on patient inhalation force;
• better stability under elevated humidity;
• fewer device rejects during manufacturing.

A commodity lactose product is unlikely to command strong pricing unless it has validated performance in a specific inhaler platform.

Alternative carrier systems

Mannitol, trehalose, sucrose, and other sugars can be evaluated as lactose alternatives. Their commercial use would face a higher regulatory burden because the safety and inhalation history of the excipient may differ from lactose.

Potential advantages include lactose-free labeling, control over hygroscopicity, and compatibility with patients who have milk-protein allergy concerns. Potential disadvantages include higher development cost, altered powder mechanics, greater moisture sensitivity, and the need for new toxicology and inhalation-safety justification.

Carrier-free engineered particles

Spray-dried or spray-freeze-dried salmeterol particles could reduce dependence on a coarse carrier. These systems may use phospholipids, amino acids such as L-leucine, or sugar matrices to improve dispersibility.

A carrier-free system could support:

• smaller fill weights;
• improved respirable fraction;
• more compact inhalers;
• reduced dependence on inspiratory flow;
• differentiated positioning for patients with limited inhalation capacity.

The main barriers are particle engineering, stability, scale-up, device compatibility, and regulatory comparability against the established lactose-based product.

Excipient-enabled combination products

The larger opportunity is combination therapy. Serevent’s LABA mechanism is clinically relevant to inhaled corticosteroid combinations and, in COPD, to combinations with long-acting muscarinic antagonists.

An excipient platform that supports stable co-formulation of salmeterol with an inhaled corticosteroid could be used to pursue:

• salmeterol/fluticasone products;
• salmeterol/budesonide products;
• triple LABA/LAMA/inhaled-corticosteroid products;
• lower-dose maintenance products;
• formulations with improved deposition matching between active ingredients.

Combination products create technical problems that a single-active formulation does not. The excipient must support uniform distribution of drugs with different particle sizes, densities, crystallinity, and surface energies. It must also avoid chemical interaction between the LABA and corticosteroid.

What formulations are protected by Serevent-related patents?

The original Serevent estate was centered on salmeterol, its salts, pharmaceutical compositions, and inhalation delivery. Those legacy composition and active-ingredient patent barriers are no longer the main commercial constraint.

Current opportunities are more likely to depend on narrower patents covering:

• engineered lactose carriers;
• specific particle-size distributions;
• spray-dried salmeterol particles;
• device-dose-metering systems;
• blister materials and moisture barriers;
• manufacturing processes;
• specific salmeterol combinations;
• inhaled corticosteroid/LABA ratios;
• methods of treating asthma or COPD with defined dosing regimens.

A formulation patent is commercially meaningful only if it covers a product feature that a competing manufacturer must use. Broad claims to lactose, salmeterol, or routine dry-powder blending are more vulnerable to invalidity or design-around arguments.

When does Serevent lose exclusivity?

Serevent’s active-ingredient exclusivity is historical rather than prospective. The product was approved in the United States in 1996, and the principal commercial value of its original patent estate has expired. [2]

Exclusivity category	Serevent position
New chemical entity exclusivity	Expired
Original salmeterol composition protection	Historical and expired
Original product patent strategy	No longer the primary barrier
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Current commercial barrier	Inhaler design, formulation performance, regulatory equivalence, and manufacturing

Serevent is a small-molecule inhalation product, not a biologic. Biosimilar exclusivity and biosimilar substitution rules do not apply. Competition would proceed through generic or follow-on inhalation pathways, typically involving an abbreviated new drug application or another FDA pathway depending on the product design. [3]

What is the Orange Book status of Serevent?

The FDA Orange Book is the authoritative source for current patent and exclusivity listings associated with an FDA-approved drug product. Serevent Diskus is listed under its approved inhalation product record, while the practical relevance of any legacy listing depends on its expiration date and whether it covers the marketed device, formulation, or method of use. [4]

For a competitive assessment, the relevant questions are:

• whether any patent remains listed for the exact Serevent dosage form;
• whether a listed patent covers the Diskus device or only a historical formulation;
• whether a generic applicant could certify Paragraph IV;
• whether the reference product has eligible regulatory exclusivity;
• whether the proposed generic can establish pharmaceutical equivalence and bioequivalence.

A Paragraph IV certification would create litigation risk only if an unexpired, listed patent remained relevant to the proposed product. For an old salmeterol product, the more material development risk is likely to be FDA equivalence, device performance, and commercial scale-up rather than the original active-ingredient patent.

Which companies are challenging Serevent or competing with it?

Competition is divided among three groups:

Competitor group	Examples	Main competitive basis
Brand LABA products	Arcapta Neohaler, Striverdi Respimat	Alternative LABA molecule or device
LABA/inhaled corticosteroid products	Advair, AirDuo, Wixela, Breo	Asthma and COPD combination therapy
LABA/LAMA products	Anoro, Stiolto, Bevespi	COPD maintenance and device differentiation
Generic or follow-on manufacturers	Potential ANDA applicants	Price, device equivalence, payer access

Serevent faces a structural disadvantage in asthma because LABA therapy is generally paired with an inhaled corticosteroid. Its standalone commercial niche is therefore narrower than the market for fixed-dose combination inhalers. [1]

What manufacturing and intellectual-property barriers remain?

The principal barriers are technical and regulatory.

Powder blending

Salmeterol is administered at a microgram-scale dose. A manufacturer must demonstrate uniform drug distribution across individual blisters and throughout the batch. Segregation during transfer, vibration, or filling can create dose variability.

Moisture control

DPI powders are sensitive to humidity. Moisture can increase particle cohesion, alter lactose surface properties, and reduce emitted dose. Blister foil, laminate construction, sealing conditions, and secondary packaging are therefore part of the commercial formulation strategy.

Device equivalence

A follow-on product must match or adequately demonstrate equivalence in delivered dose, aerodynamic particle-size distribution, and clinical performance. Device resistance, mouthpiece geometry, blister opening, powder deagglomeration, and dose counting can all affect the result.

Milk-protein management

A lactose supplier serving this market must control and characterize potential milk-protein contamination. A lactose-free or non-dairy carrier could create a differentiated product, but it would need a complete inhalation safety and regulatory package.

Process patents

Manufacturing patents may cover carrier conditioning, blending order, sieving, drug micronization, filling, blister formation, or device assembly. These patents can be more relevant than expired salmeterol patents if they claim process steps that improve dose uniformity.

How strong is the Serevent patent estate?

The legacy Serevent patent estate is weak as a blocking strategy because the original active-ingredient and product protections are expired or commercially aged. A new entrant could still create a defensible position around a specific formulation, device, manufacturing process, or combination therapy.

Patent layer	Relative strength today
Salmeterol molecule	Low
Salmeterol xinafoate composition	Low
Lactose as a carrier	Very low
Narrow carrier engineering	Moderate if clinically linked
Device and dose metering	Moderate to strong if difficult to design around
Combination formulation	Moderate to strong depending on claim scope
Manufacturing process	Moderate if process is necessary for performance
Method of use	Variable and vulnerable to label carve-outs

The strongest strategy is an integrated formulation-device claim set supported by comparative data. A patent that claims only an excipient identity is less durable than one that links excipient properties to a defined aerodynamic or dose-delivery result.

How does Serevent compare with competing inhaled LABA products?

Product	LABA	Formulation platform	Strategic position
Serevent Diskus	Salmeterol	Lactose-based DPI	Legacy standalone LABA
Striverdi Respimat	Olodaterol	Soft-mist inhaler	Device-led delivery
Arcapta Neohaler	Indacaterol	Capsule-based DPI	Once-daily COPD positioning
Advair/Wixela	Salmeterol plus fluticasone	DPI or inhalation aerosol	Combination therapy
Breo Ellipta	Vilanterol plus fluticasone furoate	DPI	Once-daily combination
Anoro Ellipta	Vilanterol plus umeclidinium	DPI	LABA/LAMA COPD therapy

Serevent’s main weakness is dosing frequency and standalone positioning. Its main technical advantage is a mature, established lactose-carrier DPI platform with extensive clinical and manufacturing precedent.

What generic launch scenarios exist for Serevent?

A generic entrant could pursue several routes:

1. A directly equivalent lactose-based salmeterol DPI using a comparable multidose device.
2. A device-substituted product with equivalent performance and clinical bridging.
3. A capsule-based salmeterol DPI with a new device and separate dose presentation.
4. A salmeterol combination product targeting the clinically preferred asthma use case.
5. A lactose-free or milk-protein-controlled product aimed at a differentiated patient segment.

The first route offers the simplest regulatory logic but the least differentiation. The fourth and fifth routes may offer better commercial positioning but require greater clinical, formulation, and regulatory investment.

What licensing opportunities exist around Serevent excipients?

Potential licensing targets include:

• inhalation-grade lactose with controlled surface properties;
• proprietary carrier conditioning processes;
• low-dose blending technology;
• spray-dried salmeterol particles;
• moisture-resistant blister systems;
• inhalers designed for low inspiratory flow;
• lactose-free carrier platforms;
• combination-DPI technology for LABA and corticosteroid products.

A commercially attractive deal would require more than a general excipient supply agreement. The strongest licensing assets would include freedom-to-operate analysis, inhalation safety data, comparative aerodynamic performance, validated manufacturing methods, and compatibility with a specific inhaler device.

Key Takeaways

• Serevent Diskus uses salmeterol xinafoate with lactose monohydrate as the principal excipient.
• The formulation is a low-dose, carrier-based DPI in which lactose controls powder handling and drug dispersion.
• The original salmeterol patent opportunity is largely exhausted; new value must come from formulation, device, manufacturing, or combination-product claims.
• Engineered lactose, moisture control, carrier-free particles, and lactose-free systems are the main excipient opportunities.
• Serevent is a small molecule and has no biosimilar risk.
• Generic competition would be shaped by inhaler equivalence, dose uniformity, aerodynamic performance, device manufacturing, and payer economics.
• The strongest new patent strategy links a defined excipient or process to a measurable inhalation-performance benefit.
• Combination therapy is commercially more attractive than standalone salmeterol in asthma because FDA labeling requires LABA use with an inhaled corticosteroid.

FAQs

Can lactose be replaced in a Serevent-type inhaler?

Yes. Mannitol, trehalose, engineered sugar particles, and carrier-free spray-dried systems are possible alternatives. Each would require formulation development, inhalation safety assessment, stability testing, and FDA comparability support.

Does Serevent contain a propellant?

Serevent Diskus is a dry-powder inhaler and does not use a hydrofluoroalkane propellant. Propellant-related reformulation issues apply to metered-dose inhalers, not the Diskus powder platform.

Is Serevent suitable for patients with milk allergy?

The product label warns that the lactose may contain milk proteins and contraindicates use in patients with severe milk-protein hypersensitivity. [1]

Could a new excipient create a patentable Serevent follow-on product?

Yes, but patentability would be stronger where the excipient is part of a defined formulation or process that produces unexpected or measurable performance, such as improved fine-particle dose, reduced humidity sensitivity, or more consistent delivery at low inspiratory flow.

Is a salmeterol product at risk from biosimilars?

No. Salmeterol is a chemically synthesized small molecule. Any competition would involve generic or follow-on inhalation products, not biosimilar regulation.

Sources:

1. U.S. Food and Drug Administration. (2023). Serevent Diskus prescribing information.
2. U.S. Food and Drug Administration. (1996). Serevent Diskus approval materials and labeling.
3. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally inhaled drug products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.